OncoMed Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, OncoMed Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
OncoMed Pharmaceuticals: 25 sponsored US clinical trials, none currently recruiting.
OncoMed Pharmaceuticals sponsors 25 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 20 completed. 0 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.
Top-decile sponsor footprint
OncoMed Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
25 total, page 1 of 1
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
NCT03295942
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03119428
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
NCT03031691
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
NCT03030287
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
NCT03035253
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
NCT02722954
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
NCT02482441
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT02289898
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
NCT02092363
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
NCT02069145
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
NCT02050178
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
NCT01957007
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
NCT02005315
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
NCT01973309
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
NCT01952249
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
NCT01778439
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
NCT01703572
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
NCT01647828
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
NCT01608867
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
NCT01345201
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
NCT01277146
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
NCT00744562
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 2 |
Therapeutic Areas
How the OncoMed Pharmaceuticals early-phase archive is shaped
25 indexed studies, none listed as recruiting (0% open); 20 completed (80%).
Phase mix: 0 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
OncoMed Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 25 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
OncoMed Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 archived trials
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this OncoMed Pharmaceuticals page
25 registered trials is a research-attention snapshot, not an endorsement of OncoMed Pharmaceuticals or any single study.
- None of OncoMed Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Solid Tumors is the condition OncoMed Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. OncoMed Pharmaceuticals pipeline card: 25 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.